Items of recent pandemic news: Boosters approved for kids 5-11; the cause of severe Covid-19; two new vaccines built on different technology bases; immune evasiveness of two Omicron sub-variants; Paxlovid developments; and much more. Plus a frippery. The pandemic sputters … Continue reading →
Items of recent pandemic news: Moderna announces preliminary results for their vaccine in children; the White House rolls out the one-stop information site covid.gov; FDA authorizes a fourth shot for older adults; and much more. Plus a frippery. Apologies to … Continue reading →
Items of recent pandemic news: Antihistamines may help some long Covid; J&J pauses manufacturing vaccine; FDA authorizes Eli Lilly’s injectable monoclonal; how boosters wane; and a further delay in shots for the youngest children. Plus a frippery. Quote of the … Continue reading →
Items of recent pandemic news: Omicron boosters prove unhelpful; wastewater surveillance comes into its own; Covid-19 causes long-term heart and circulatory issues; results from the first SARS-CoV-2 challenge trial published; and more. Plus two fripperies. Quote of the week Eric … Continue reading →
Items of recent pandemic news: Historical perspective and promising research on long Covid; beginning Omicron-targeted vaccine trials; press attention for a new CBD study; Hong Kong’s zero-Covid strategy and Omicron; and BA.2 in the US. Plus a frippery. Quotes of … Continue reading →
Items of recent pandemic news: A resource for finding authorized therapeutics in the US; how long booster shots protect; an early study isolating ultrapotent antibodies from elite neutralizers; and a new variant on the Omicron variant. Plus a frippery. Quotes … Continue reading →
Items of recent pandemic news: Minnesota’s oddly bright prospects; Israel offers a fourth shot; the end of the pandemic as a social phenomenon; and what happens when Omicron hits a population with pre-existing immunity. Plus a frippery. Quotes of the … Continue reading →
Items of recent pandemic news: Those who pay zero attention to the pandemic; the evolutionary weirdness of Omicron; the class-based roots of vaccine avoidance; boosters authorized for people aged 16-17; and Paxlovid’s continuing promise. Plus a frippery. Paxlovid holds up … Continue reading →
Items of recent pandemic news: Quantifying the immunity advantage over natural infection that you get from boosting; nucleotide sequences released for the vaccines; an update on Omicron; and what we should do about it right now. Plus a frippery. Quotes … Continue reading →
Items of recent pandemic news: How the sex of the fetus affects a mother’s immune response to the coronavirus; the prospect for vaccination in ages 5-11; boosters authorized in mix-and-match format; and more. Plus a frippery. Boosters for most everyone … Continue reading →
Items of recent pandemic news: Auto-antibodies in long Covid; Moderna’s durability benefit over Pfizer; results from Johnson & Johnson’s two-dose trial; Pfizer’s effectiveness in kids 5-11; and who gets a Pfizer booster. Plus a frippery. FDA, CDC committee approve boosters … Continue reading →
Items of recent pandemic news: How to fix indoor air; Covid-sniffing dogs at Miami airport; an account of a “mild” breakthrough case of Covid-19; and today’s pivotal FDA meeting on boosters. Plus two fripperies. The booster debate comes to a … Continue reading →
Items of recent pandemic news: Vaccination halves chances of long Covid; the role of auto-antibodies in severe disease; rising out-of-pocket costs of Covid; the unlikelihood that September 20 will see booster shots; and more. Plus a frippery. 1. Boosters will … Continue reading →
Two senior FDA officials have resigned — “giants who helped bring us many safe and effective vaccines over decades of public service,” according to a former FDA scientist — reportedly in protest of political meddling in the work of the … Continue reading →
Items of recent pandemic news you may have missed: Delta Air Lines’ strong encouragement for vaccination; contaminated vaccine in Japan; good news on a J&J booster; and the dent approval is not making in vaccine hesitancy. Plus two fripperies. Approval … Continue reading →
